[Efficacy of transcatheter arterial infusion chemotherapy and transcatheter arterial embolization in 132 patients with primary hepatocellular carcinoma].
To find out factors influencing efficacy of transcatheter arterial infusion chemotherapy (TAI) and transcatheter arterial embolization (TAE) for unresectable primary hepatocellular carcinoma. From January 1993 to October 1997, 132 patients with unresectable primary hepatocellular carcinoma (HCC) received 597 intervention treatments. Of the 132 patients, 122 patients were given TAI plus TAE (92.4%), while the remaining 10 patients were given TAI alone (7.6%). The 1-, 2-, and 3-year overall survival rate was 81.8%, 36.4% and 18.2%, respectively. The clinical stage of the disease, the embolizing agents used and their dosage, formation of collateral circulation to the tumor and proper application of superselective hepatic arterial catheterization are factors affecting treatment efficacy. Adequately performed TAI and TAE can be routinely used for the treatment of unresectable liver cancer.